Gocovri Alternatives Compared
| Gocovri (amantadine) | Carbidopa / levodopa | Sinemet (carbidopa / levodopa) |
|
|---|
| Gocovri (amantadine) | Carbidopa / levodopa | Sinemet (carbidopa / levodopa) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Gocovri may be used to treat dyskinesia or reduce the number of OFF episodes in those with Parkinson's disease. Hallucinations are a common side effect and it may cause a low mood or intense urges to... View more |
Prescription only
Carbidopa/levodopa is a medication that may be used for the treatment of Parkinson's disease. Available as immediate-release tablets, extended-release tablets, and extended-release capsules... View more |
Prescription only
Sinemet is a medication that may be used for the treatment of Parkinson's disease that is available in three different strengths: Sinemet 25/100, Sinemet 25/250, and Sinemet 10/100. Dyskinesias... View more |
Related suggestions Parkinson's Disease
Popular comparisons
|
|||||||||||||||||||||||
| More about Gocovri (amantadine) | More about Carbidopa / levodopa | More about Sinemet (carbidopa / levodopa) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Gocovri has an average rating of 8.0 out of 10 from a total of 2 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Carbidopa / levodopa has an average rating of 7.3 out of 10 from a total of 94 ratings on Drugs.com. 65% of reviewers reported a positive effect, while 20% reported a negative effect. |
Sinemet has an average rating of 7.8 out of 10 from a total of 30 ratings on Drugs.com. 68% of reviewers reported a positive effect, while 11% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
|
View all Gocovri side effects |
View all Carbidopa / levodopa side effects |
View all Sinemet side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
Lower cost generic |
||||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Gocovri prices |
View all Carbidopa / levodopa prices |
View all Sinemet prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Other amantadine brands include: Osmolex ER | Atamet, Crexont, Dhivy, Duopa, Parcopa, Rytary, Sinemet | Other carbidopa / levodopa brands include: Atamet, Crexont, Dhivy, Duopa, Parcopa, Rytary | ||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
19 hours |
2.3 hours |
2.3 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 130 drugs are known to interact with Gocovri:
|
A total of 499 drugs are known to interact with Carbidopa / levodopa:
|
A total of 499 drugs are known to interact with Sinemet:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
|
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
August 24, 2017 |
May 02, 1975 |
May 02, 1975 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.